The Myeloperoxidase antibody has been shown to be a specific marker for myeloid cells and has been used in a panel for immunophenotyping acute lymphoblastic leukemia in bone marrow biopsies. Myeloperoxidase (MPO) is readily detected in myeloblasts and immature myeloid cells of acute myelogenous leukemia, progranulocytic leukemia, progranulocytic leukemia, monomyelocytic leukemia, erythroleukemia, myeloblastomas and other hematopoietic disorders. Aberrant MPO expression has been found to occur in non-myeloid cells in some disease states, including lung and ovarian cancers.
Any tissue with inflammatory process, such as colon cancer or tonsil
1. Toth B, Wehrmann M, Kaiserling E, Horny HP. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. J Clin Pathol 1999 Sep;52(9):688-92
2. Pinkus GS, Pinkus JL. Myeloperoxidase: a specific marker for myeloid cells in paraffin sections. Mod Pathol 1991 Nov;4(6):733-41.
3. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
4. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova, PA 1991;7(9). Order code M29-P.